EGFR and colonic neoplasm: Key evidence from colon cancer suggests that BRAF (V600E)-mutant tumors are not responsive to vemurafenib alone but only in combination with an EGFR inhibitor to repress the rapid feedback activation of EGFR by vemurafenib treatment (98).